Emergex Vaccines expands at Milton Park
Published on 2 March 2021
Emergex Vaccines, which focuses on the development of synthetic T-cell vaccines against global infectious disease threats such as COVID-19, Dengue fever, Zika, Ebola and pandemic Flu, has expanded at Milton Park.
Emergex’s vaccines are designed to prime recipients’ immune systems to recognise infections much like a natural infection would, in order to protect people from disease. Their vaccines are 100% synthetic – requiring no biology for manufacturing – and therefore have the potential to be rapidly produced and cost-effectively scaled. They are delivered through a microneedle system which allows for convenient administration through a patch and require no cold chain in storage or distribution.
Emergex employs circa 30 people, and as part of the recent expansion, the company has taken 2,787 sq ft at 66 Innovation Drive, which is in addition to its R&D facility at 65 Innovation Drive, bringing its total occupation to 8,724 sq ft.
Storme Moore-Thornicroft, co-founder and COO of Emergex commented: “The current COVID-19 pandemic has put vaccines in the spotlight like never before. We believe that our vaccine technology can play a critical role in creating safe, effective vaccines that can be rapidly and widely deployed against some of the most pressing disease threats in the world. Our expansion at Milton Park, at the heart of the Oxfordshire sciences ecosystem, reflects our continued growth, and we look forward to working in these facilities to further advance our pipeline.”
Philip Campbell, MEPC commercial director, Milton Park said: “Emergex Vaccines needed expansion space, and we were pleased to accommodate their growth plans. The work the team is doing to address serious infectious diseases across the world through its highly innovative vaccine technology is very impressive, and we were very happy to assist them.”